All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How should duration of response be defined?

Jul 22, 2022
Learning objective: After listening to this discussion, learners will be able to cite how to define response in GvHD.

During the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion leaders met to debate how duration of response should be defined. The recorded discussion was chaired by Mohamad Mohty and featured Amin Alousi, Ali Bazarbachi, Hildegard Greinix, and Attilio Olivieri.

How should duration of response be defined?

Mohty begins by stating that it is only recently, with the approval of agents for GvHD treatment, that the question of how to define response has become a concern. Bazarbachi discusses the importance of achieving an ongoing response rather than a transient one to improve outcomes in acute GvHD. The steering committee contemplate how the side effects of treatment can result in early initiation of the next line of therapy, and the impact of organ damage on response definition is also considered.